

CV Date	18/04/2023
---------	------------

Part A. PERSONAL INFORMATION

First Name *	Beatriz		
Family Name *	Soldevilla Navarro		
Sex *	Female	Date of Birth *	19/10/1984
ID number Social Security, Passport *	47300959X	Phone Number *	(+34) 917792708 - 4708
URL Web	https://www.linkedin.com/in/beatriz-soldevilla-navarro-15b9b939?trk=hp-identity-n		
Email Address	beatriz_soldevilla_navarro@hotmail.com; bsoldevilla.imas12@h12o.es		
Researcher's identification number	Open Researcher and Contributor ID (ORCID) *	0000-0002-1118-1316	
	Researcher ID	F-6835-2016	
	Scopus Author ID		

* Mandatory

A.1. Current position

Job Title	Investigadora Asociada		
Starting date	2022		
Institution	Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre		
Department / Centre			
Country		Phone Number	
Keywords			

A.2. Previous positions

Period	Job Title / Name of Employer / Country
2017 - 2022	Investigador Postdoctoral (Beca Postdoctoral AECC 2017) / Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre
2016 - 2017	Investigador Postdoctoral / Fundación para la investigación Biomédica del Hospital 12 de Octubre
2015 - 2016	Investigador Postdoctoral / Universidad Autónoma de Madrid
2014 - 2015	Investigador Postdoctoral / Instituto Investigación Biomédica "Alberto Sols"-CSIC-UAM
2009 - 2014	Investigador Predoctoral / Fundación para la Investigación Biomédica Hospital Universitario Puerta de Hierro-Majadahonda
2007 - 2008	Proyecto Final Carrera / Instituto Cajal-CSIC
2007 - 2007	Prácticas laboratorio (Practicum) / Instituto Cajal-CSIC

A.3. Education

Degree/Master/PhD	University / Country	Year
Licenciado en Biología	Universidad Autónoma de Madrid	2015
PhD en Bioquímica, Biología Molecular y Biomedicina	Universidad Autónoma de Madrid	2014
Máster Biología Molecular y Celular	Universidad Autónoma de Madrid	2011
Licenciado en Bioquímica	Universidad Autónoma de Madrid	2008

A.4. General quality indicators of scientific production

h-Index: 12. Total citations: 706. Author of 20 papers, 6 of them D1 and 12 Q1.

Part B. CV SUMMARY

Beatriz Soldevilla (BS) has degree in Biochemistry and Biology, a Máster's Degree in Molecular and Cellular Biology, and a PhD in Biochemistry, Molecular Biology and biomedicine (Autonomous University of Madrid). She started her research career in the oncology field in the laboratory of Molecular Genetics of Cancer led by Dr. Félix Bonilla Velasco where was involved in several research projects related with digestive tumors. After this predoctoral time, she moved to the Mitochondrial Pathology laboratory led by Dr. Jose M. Cuezva in the Centro de Biología Molecular Severo Ochoa (CBMSO-CSIC), where she developed her skills in basic research and she also was co-investigator in several projects related to mitochondrial pathology including cancer. Thus, as postdoctoral researcher she was focused on the study of DNA damage and repair mechanisms, drug resistance models, and she obtained an extensive experience in preclinical models. In 2016, she joined to the Gastrointestinal and Neuroendocrine Tumors Group (GI&NET) headed by Dra. Rocío García-Carbonero, and together, led the research laboratory which is part of the Clinical and Translational Oncology Laboratory from 12 de Octubre Research Institute led by Dr. Luis Paz-Ares. Since 2016, the GI&NET group has exponentially grown in terms of research projects, academic production and human resources dedicated to translational research. In this context, as IP part of GI&NET group, BS has developed as a senior researcher being co-director of the group's projects and coordinating experimental work and laboratory management, including mentoring pre-doctoral fellows and other relevant leadership roles. More specifically, she has been IP of a project funded by GETNE group in 2019, and the director of a PhD fellowship also awarded in 2019 by the Asociación Española contra el cáncer (AECC). In addition, BS is the scientific coordinator of the ongoing translational study associated to AXINET (EudaCT2011-001550-29) and NICE-NEC (GETNE-T1913) that have recruited tumor, blood and urine samples from national and international centers.

Several projects with active participation or leadership of BS have produced several publications (10.1210/edrv/bnad006; 10.1002/1878-0261.13393; 10.3390/cancers13112634; 10.1016/j.chroma.2020.461233; 10.1016/j.ejca.2019.09.008) and multiple conference presentations, where BS shows principal positions (see BS CVA).

As evidence of transfer activity to the productive sector, the profile of BS shows two patents (P201331371; P202131016), the most recent related with relevant data published in 10.1002/1878-0261.13393 where BS is first and corresponding author.

BS is currently Associate Professor at UCM and regarding postgraduate teaching and mentoring, she has been involved in the Translational Research UCM Master's Degree. She has mentored several TFGs and TFMs and has directed 2 Doctoral Theses (+5 additional ones ongoing).

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Publications

AC: corresponding author. (n° x / n° y): position / total authors. If applicable, indicate the number of citations

- 1 **Scientific paper.** Rocío García-Carbonero; Beatriz Anton-Pascual; Andrea Modrego; María del Carmen Riesco-Martínez; Alberto Lens-Pardo; Carlos Carretero-Puche; Beatriz Rubio-Cuesta; Beatriz Soldevilla. (8/8). 2022. Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: are we moving forward?. Endocrine Reviews (Senior Position, Q1, D1). <https://doi.org/10.1210/edrv/bnad006>
- 2 **Scientific paper.** Beatriz Soldevilla; Alberto Lens-Pardo; Paula Espinosa-Olarte; et al; Rocío García-Carbonero. (1/18). 2022. MicroRNA signature and integrative omics analyses to define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms. Molecular Oncology (First Position, Corresponding Author , Q1). ISSN 1574-7891. <https://doi.org/10.1002/1878-0261.13393>

- 3 **Scientific paper.** (1/14)Beatriz Soldevilla; Angeles Lopez-Lopez; Alberto Lens-Pardo; et al; Rocio Garcia-Carbonero. 2021. Comprehensive plasma metabolomic profile of patients with advanced Neuroendocrine tumors (NETs). Diag-nostic and biological relevance.Cancers (First position, Q1,actualizado JCR 2021). ISSN 1078-0432. <https://doi.org/10.3390/cancers13112634>.
- 4 **Scientific paper.** (3/10)Angeles López-López; Joanna Godzien; Beatriz Soldevilla; et al; Coral Barbas. 2020. Oxidized lipids in the metabolic profiling of neuroendocrine tumors - Analytical challenges and biological implications. JOURNAL OF CHROMATOGRAPHY A (Third position, Q1, actualizado JCR 2021). 1625-461233. ISSN 0021-9673. <https://doi.org/10.1016/j.chroma.2020.461233>
- 5 **Scientific paper.** (1/13)Beatriz Soldevilla; Carlos Carretero-Puche; Gonzalo Gomez-Lopez; et al; Rocio Garcia Carbonero. 2019. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.European Journal of Cancer (First position, Q1, actualizado JCR 2021). 123, pp.10.1016/j.ejca.2019.09.008. ISSN 0959-8049. <https://doi.org/10.1016/j.ejca.2019.09.008>
- 6 **Scientific paper.** (8/11)Julia Martinez-Perez; Iker Lopez-Calderero; Carmen Sáez; et al; Rocio García-Carbonero. 2017. Prognostic relevance of Src activation in stage II-III colon cancer. Human Pathology (Eighth position, Q2, actualizado JCR 2021). 67, pp.119-125. ISSN 0046-8177. <https://doi.org/10.1016/j.humpath.2017.05.025>
- 7 **Scientific paper.** (1/14)Beatriz Soldevilla; Carmen Cuevas-Martín; Clara Ibañez; et al; Jose M Cuezva. (1/14). 2017. Plasma-metabolite and skin-protein signatures of Charcot-Marie-Tooth 1A provide molecular markers of disease and suggest future therapeutic interventions. Plos One Jun 2;12(6):e0178376. (First position, Q2, actualizado JCR 2021). ISSN 1932-6203. <https://doi.org/10.1371/journal.pone.0178376>
- 8 **Scientific paper.** Lucía García-Ledo; Cristina Nuevo-Tapioles; Carmen Cuevas-Martin; Inmaculada Martínez-Reyes; Beatriz Soldevilla; Lucía González-LLorente; Jose M Cuezva. 2017. Overexpression of the ATPase Inhibitory Factor 1 Favors a Non-metastatic Phenotype in Breast Cancer.Frontiers in Oncology (Fifth position, Q2 actualizado JCR 2021). 7-69. ISSN 2234-943X. <https://doi.org/10.3389/fonc.2017.00069>
- 9 **Scientific paper.** Marta Rodríguez; Javier Silva; Alberto Herrera; et al; Vanesa García. 2015. Exosome enriched in stemness/metastatic-related mRNAs promote oncogenic potential in breast cancer. Specific prognostic exosome signature. Oncotarget (Tenth position, Q1, D1). 6-38, pp.40575-40587. Q1. <https://doi.org/10.18632/oncotarget.5818>
- 10 **Scientific paper.** Coral San Millán; Beatriz Soldevilla; Paloma Martín; et al; Gemma Domínguez. 2015. Beta-cryptoxanthin synergistically enhances cytotoxicity of oxaliplatin through DeltaNp73 negative regulation in colon cancer. Clinical Cancer Research (Second position, Q1, D1 actualizado JCR 2021). 21-19, pp.4398-4409. D1. ISSN 1078-0432.
- 11 **Scientific paper.** Javier García-Bermúdez; María Sánchez-Argó; Beatriz Soldevilla; Araceli del Arco; Cristina Nuevo-Tapioles; Jose M Cuezva. 2015. PKA phosphorylates the ATPase Inhibitory Factor 1 (IF1) and inactivates its capacity to bind and inhibit the mitochondrial H⁺-ATP synthase.Cell Report (Third position, Q1 actualizado JCR 2021). 12, pp.2143-2155. D1. ISSN 2211-1247. <https://doi.org/10.1016/j.celrep.2015.08.052>
- 12 **Scientific paper.** Beatriz Soldevilla; Marta Rodríguez; Coral San Millán; et al; Gemma Domínguez. 2014. Tumor-derived exosomes are enriched in DeltaNp73, promote oncogenic potential to acceptor cells and correlate with patients survival. Human Molecular Genetics (First position, Q1, actualizado JCR 2021). 2-23, pp.467-478. D1. ISSN 0964-6906. <https://doi.org/10.1093/hmg/ddt437>
- 13 **Scientific paper.** Carmen Herrero; Beatriz Soldevilla; Belén Pérez; Inmaculada Blanco; Mercedes Herrera; Félix Bonilla; Fernando Granado; Gemma Domínguez. 2013. Modulation of DNA-induced damage and repair capacity in humans after dietary intervention with lutein enriched fermented milk. Plos One (Second position, Q2, actualizado 2021). 9-8, pp.e74135-Q1. ISSN 1932-6203. <https://doi.org/10.1371/journal.pone.0074135>

- 14 Scientific paper.** Beatriz Soldevilla; Coral San Millán; Félix Bonila; Gemma Domínguez. 2013. TP73:ready for clinical translation?. Genes, Chromosomes and Cancer (First position, Q2, actualizado JCR 2021). 11-52, pp.989-1006. Q2. <https://doi.org/10.1002/gcc.22095>
- 15 Scientific paper.** Mercedes Herrera; Alberto Herrera; Gemma Domínguez; et al; Cristina Peña. 2013. Cancer-associated fibroblast and M2 macrophage marker together predict outcome in colorectal cancer patients. Cancer science (Eighth position, Q2 actualizado JCR 2021). 4-104, pp.437-444. Q2.
- 16 Scientific paper.** RG Urduñigo; AF Fernández; A Moncada-Pazos; et al; Mario F Fraga. 2013. Immune dependent and independent anti-tumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors. Cancer Research (Fourteenth position, Q1,D1 actualizado JCR 2021). 1-33, pp.395-405. D1.
- 17 Scientific paper.** RM Rodríguez; C Huidobro; RG Urduñigo; et al; Mario F Fraga. 2012. Aberrant epigenetic regulation of bromodomain Brd4 in human colon cancer. Journal of Molecular Medicine (Fifth position, Q1, actualizado JCR 2021)). 5-90, pp.587-595. Q1.
- 18 Scientific paper.** Beatriz Soldevilla; Raquel Díaz; Javier Silva; et al; Gemma Domínguez. 2011. Prognostic impact of DeltaTAp73 isoforms levels and their target genes in colon cancer patients. Clinical Cancer Research (First position, Q1,D1 actualizado JCR 2021). 18-17, pp.6029-6039. D1.
- 19 Scientific paper.** Raquel Díaz; Jose M González-Sancho; Beatriz Soldevilla; et al; Gemma Domínguez. 2010. Differential regulation of p73 isoforms by 1alpha,25-dihydroxyvitamin D3 in a survivin-dependent manner in human colon and breast carcinomas. Genes, Chromosomes and Cancer (Third position, Q2 actualizado JCR 2021). 12-49, pp.1135-1142. Q2.
- 20 Scientific paper.** Beatriz Rubio-Cuesta; Carlos Carretero-Puche; Patricia Llamas; et al; Rocio García-Carbonero. Targeting SRC as a novel therapeutic strategy in BRAF mutated colorectal cancer (Submitted). (Last position, corresponding author).

C.2. Conferences and meetings

- 1** Carlos; Beatriz; Alberto; et al; Rocio. Multi-omic factor analysis (MOFA) of well-differentiated neuroendocrine tumors (NETs) from different tumor sites. 1st ENETS Basic and Translational NET Research – A Forum on Basic and Translational Science in Neuroendocrine Neoplasms. 2023.
- 2** Alberto Lens-Pardo; Carlos Carretero-Puche; Beatriz Antón-Pascual; et al; Rocio Garcia-Carbonero. Predictive transcriptomic signature of response to axitinib in patients with advanced NETs included in the randomized, double-blind, placebo-controlled AXINET trial (GETNE 1107). 20th Annual ENETS Conference. 2023. Austria.
- 3** Beatriz Rubio-Cuesta; Carlos Carretero-Puche; Alberto Lens-Pardo; et al; Beatriz Soldevilla. Comprehensive molecular study of Src as a potential therapeutic target in BRAF V600E colorectal cancer. 18th ASEICA International Congress. 2022. Spain.
- 4** Carlos Carretero-Puche; Beatriz Anton-Pascual; Alberto Lens-Pardo; et al; Rocio Garcia-Carbonero. Development of a tumor-site independent multiomic model of neuroendocrine neoplasias of potential clinical use. 18th ASEICA International Congress. 2022. Spain.
- 5** Alberto Lens-Pardo; Carlos Carretero-Puche; Beatriz Anton-Pascual; et al; Rocio Garcia-Carbonero. Predictive biomarkers of response to anti angiogenic therapy in NETs. 18th ASEICA International Congress. 2022. Spain.
- 6** Alberto Lens-Pardo; Paula Espinosa-Olarte; Carlos Carretero-Puche; et al; Beatriz Soldevilla. 8-miRNAs signature defines prognostic clusters in NENs and identifies key oncogenic pathways involved in NENs biology. EACR 2022 Congress - Innovative Cancer Science: Translating Biology to Medicine. 2022. Spain.
- 7** Beatriz Rubio-Cuesta; Beatriz Gil-Calderon; Patricia Llamas-Granda; et al; Rocio Garcia-Carbonero. Comprehensive study of Src as a potential therapeutic target in BRAF mutated CRC. EACR 2022 Congress - Innovative Cancer Science: Translating Biology to Medicine. 2022. Spain.

- 8 Carlos Carretero; beatriz Soldevilla; Anna La Salvia; et al; Rocio Garcia-Carbonero. Multiomic analysis in neuroendocrine neoplasias displays diverse molecular subtypes with clinical significance regardless tumor origin. EACR 2022 Congress - Innovative Cancer Science: Translating Biology to Medicine. 2022. Spain.
- 9 Carlos Carretero-Puche; Beatriz Soldevilla; Beatriz Gil-Calderon; et al; Rocio García-Carbonero. Comprehensive multiomic analysis reveals different subtypes in neuroendocrine tumors from multiple origins. AACR Annual Meeting 2022 Evento. 2022. United States of America.
- 10 Beatriz Rubio-Cuesta; Beatriz Gil-Calderon; Patricia Llamas-Granda; Jacinto Sarmentero; Carlos Carretero-Puche; Maria del Carmen Riesco-Martinez; Rocio García-Carbonero; Beatriz Soldevilla. Molecular characterization of BRAF V600E CRC in response to Src-targeted therapy. AACR Annual Meeting 2022 Evento. 2022. United States of America.
- 11 Alberto Lens-Pardo; Paula Espinosa-Olarte; Carlos Carretero-Puche; et al; Beatriz Soldevilla. Comprehensive molecular analysis of prognostic groups in Neuroendocrine Neoplasms (NENs) identifies key genes and potential regulatory mechanisms. Annual ENETS Conference: ENETS 2022. 2022.
- 12 Carlos Carretero-Puche; Beatriz Gil-Calderon; Beatriz Soldevilla; et al; Rocio García-Carbonero. Comprehensive transcriptomic and methylomic analysis of NENs from multiple origins show subgroups of patients with clinical relevance. 1st World Net Forum 2022. 2022. Spain.
- 13 Beatriz Rubio-Cuesta; Carlos Carretero-Puche; Beatriz Gil-Calderon; Patricia Llamas-Granda; Jacinto Sarmentero; Maria C Riesco-Martinez; Rocio Garcia-Carbonero; Beatriz Soldevilla. Comprehensive molecular description of BRAFV600E colorectal cancer in response to Src-targeted therapy in vitro. 3rd ASEICA Educational Symposium. 2021.
- 14 Carlos; Beatriz; Beatriz; et al; Rocio. Comprehensive transcriptomic analysis reveals different gene expression groups in neuroendocrine tumors from multiple origins.. EACR 2021 Congress:Better Outcomes Through Research. 2021.
- 15 Carlos; Maria C; Anna; Beatriz; Beatriz; Rocio; Beatriz. MiRNA signature defines prognostic clusters in NENs of lung and GEP origin: a comprehensive molecular analysis. 3rd ASEICA Educational Symposium. 2021.
- 16 Carlos Carretero; C Gomez-Lopez; Maria del Carmen Riesco; et al; Beatriz Soldevilla. Immune Subtypes in Colorectal Cancer: Molecular and Functional caracterización and their clinical implications. EACR 2021 Congress:Better Outcomes Through Research. 2021.
- 17 Beatriz; Raul; Beatriz; Beatriz; Jacinto; Carlos; Maria; Rocio. Molecular characterization of BRAF (V600E) CRC in response to Src-targeted therapy in vitro. EACR 2021 Congress: Better Outcomes Through Research. 2021.
- 18 Beatriz; Alberto; Angeles; et al; Rocio. Comprehensive metabolomic profile of patients with advanced neuroendocrine tumors. Annual ENETS Conference: ENETS 2021 Virtual. 2021.
- 19 Paula Espinosa-Olarte; Beatriz Soldevilla; Carlos Carretero-Puche; et al; Rocio Garcia-Carbonero. MicroRNA prognostic signature in neuroendocrine neoplasias (NENs) of lung and GEP origin: In silico analysis of target genes and pathways. Annual ENETS Conference: ENETS 2021 Virtual. 2021.
- 20 Beatriz Soldevilla; Alberto Lens-Pardo; Angeles López-López; et al; Rocío García-Carbonero. Metabolomic profile of advanced neuroendocrine cancer patients. ESMO VIRTUAL CONGRESS 2020. 2020. Participatory - oral communication.
- 21 Paula Espinosa-Olarte; Beatriz Soldevilla; Carlos Carretero-Puche; et al; Rocío García-Carbonero. Prognostic value of miRNA profiling in neuroendocrine neoplasias from lung and gastroenteropancreatic origin. ESMO VIRTUAL CONGRESS 2020. 2020. 'Participatory - poster.
- 22 Beatriz Soldevilla; Angeles López-López; Angeles Lopez-González; Coral Barbas; Paula Espinosa-Olarte; Anna La Salvia; Rocío García-Carbonero. Metabolomic characterization of patients with neuroendocrine tumors. 2nd ASEICA EDUCATIONAL SYMPOSIUM. 2019. 'Participatory - poster.

C.3. Research projects and contracts

- 1 Project.** MULTI-OMIC INTEGRATED ANALYSIS OF PATIENTS WITH NEUROENDOCRINE NEOPLASIAS (NENs). (Asociación Española Contra el Cáncer). 01/12/2022-01/12/2025. 300.000 €.
- 2 Project.** Caracterización del perfil inmune de las neoplasias neuroendocrinas (NENs) G3 de origen gastroenteropancreático o desconocido mediante GeoMX Digital Spatial Profiling (DSP). (GETNE). 01/01/2022-31/12/2023. 20.000 €.
- 3 Project.** Caracterización molecular del Cáncer colorrectal con inestabilidad de microsatélites (MSI-H): identificación de marcadores pronósticos y predictivos al tratamiento con inmunoterapia.. (SEOM). 01/01/2022-31/12/2023. 30.000 €.
- 4 Project.** Estudio del perfil metabólico en tumores neuroendocrinos gastrointestinales. (GETNE). 01/01/2019-31/12/2020. 40.000 €.
- 5 Project.** Caracterización Molecular de las Neoplasias Neuroendocrinas Gastrointestinales. Aplicación en el contexto clínico (BECA POSTDOCTORAL AECC 2017). (Fundación AECC (POSTDOCTORAL)). 01/08/2017-31/07/2020.
- 6 Project.** Activación de Src en cancer colorectal: estudio funcional y utilidad como biomarcador en la clínica. (FIS-Instituto de Salud Carlos III (PI16/01827)). 01/01/2017-31/12/2019. 203.000 €.
- 7 Project.** Función oncogénica de IF1: el inhibidor de la H⁺-ATP sintasa de la mitocondria.. (Fundación Ramón Areces). 02/01/2015-29/12/2017.
- 8 Project.** La mitocondria y su disfunción en patología: IF1. (Ministerio de Economía y Competitividad). 02/01/2014-30/12/2016.
- 9 Project.** Mecanismos de la inducción de quimio-resistencia por isoformas oncogénicas de p73 (Deltap73) en carcinomas de colon humanos. (FIS-Instituto de Salud Carlos III (PI11/00593)). 02/01/2012-31/12/2014. 209.714,78 €.
- 10 Project.** Mecanismos de la inducción de quimio-resistencia por isoformas oncogénicas de p73 (Deltap73) en carcinomas de colon humanos. (Fundación para la Investigación Biomédica Hospital Universitario Puerta de Hierro-Majadahonda). 02/01/2012-31/12/2013. 40.000 €.
- 11 Project.** Mecanismos de la inducción de quimio-resistencia por isoformas oncogénicas de p73 (Deltap73) en carcinomas de colon humanos. (Universidad Autónoma de Madrid). 02/01/2011-31/12/2011. 13.700 €.
- 12 Project.** CONTRATO JUAN DE LA CIERVA (FJCI-2015-27188) Convocatoria 2016. (Ministerio económica, industria y competitividad). From 2016. 50.000 €.
- 13 Contract.** Estudio fase II/III aleatorizado doble ciego de la combinación de sandostatina LAR con axitinib vs sandostatina LAR con placebo en pacientes con tumores neuroendocrinos avanzados G1-G2 (OMS 2010) de origen no pancreático (EudraCT 2011-001550-29) IP DEL ESTUDIO TRASLACIONAL:BEATRIZ SOLDEVILLA 2.658.897 €.
- 14 Contract.** NICE-NEC, a phase II study of platinum-doublet chemotherapy in combination with nivolumab as first-line treatment in subjects with unresectable, locally advanced or metastatic grade 3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic tract or of unknown origin. GETNE-T1913 IP DEL ESTUDIO TRASLACIONAL:BEATRIZ SOLDEVILLA

C.4. Activities of technology / knowledge transfer and results exploitation

- 1 P202131016.** FIRMA PRONÓSTICA DE MICRORNAS EN NEOPLASIAS NEUROENDOCRINAS (NENs) DE ORIGEN GASTROENTEROPANCREÁTICO (GEP) Y PULMONAR Spain. 28/10/2021.
- 2 201331376.** Compuestos para el tratamiento del cáncer Spain. 30/10/2013. Universidad Autónoma de Madrid, Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro-Majadahonda.